Imunon CMO granted 3,516 shares for salary

Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. reported that Chief Medical Officer Douglas Vincent Faller received a grant of 3,516 shares of common stock on 2026-08-14. The shares were valued at $1.65 per share and were granted in lieu of cash for a portion of his base salary, bringing his direct holdings to 33,451 shares.

Insider Trade Summary

Grant/Award: 3,516 shares

Grant/Award 1 txn

Insider Faller Douglas Vincent

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	3,516	$1.65	$6K

Holdings After Transaction: Common Stock — 33,451 shares (Direct)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of base salary

Key Figures

Shares granted: 3,516 shares Grant value per share: $1.65 per share Shares owned after transaction: 33,451 shares

3 metrics

Shares granted 3,516 shares Common stock granted to Chief Medical Officer on 2026-08-14

Grant value per share $1.65 per share Value used for stock granted in lieu of cash base salary

Shares owned after transaction 33,451 shares Direct holdings of Douglas Vincent Faller following the grant

Key Terms

Grant, award, or other acquisition, in lieu of cash, base salary

3 terms

Grant, award, or other acquisition financial

"transaction code description "Grant, award, or other acquisition""

in lieu of cash financial

"Stock granted in lieu of cash for portion of base salary"

base salary financial

"Stock granted in lieu of cash for portion of base salary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IMNN report for Douglas Vincent Faller?

Imunon reported that Douglas Vincent Faller received a grant of 3,516 IMNN common shares on 2026-08-14. The stock was granted in lieu of cash for part of his base salary at $1.65 per share.

How many IMNN shares did Douglas Vincent Faller acquire and at what price?

Douglas Vincent Faller acquired 3,516 IMNN common shares at a value of $1.65 per share. According to the disclosure, these shares were granted as stock compensation in lieu of cash for a portion of his base salary.

What are Douglas Vincent Faller’s IMNN share holdings after this Form 4 transaction?

After the reported transaction, Douglas Vincent Faller directly holds 33,451 shares of Imunon common stock. This reflects the addition of 3,516 shares granted on 2026-08-14 as part of his base salary compensation.

Was the IMNN Form 4 transaction a market purchase or a stock grant?

The IMNN Form 4 discloses a stock grant, not a market purchase. The 3,516 shares of common stock were granted in lieu of cash for a portion of Douglas Vincent Faller’s base salary at a stated value of $1.65 per share.

Did Imunon’s Chief Medical Officer use a 10b5-1 trading plan for this IMNN transaction?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed, and the transaction is described as a grant in lieu of cash salary, rather than a trade executed under a pre-arranged 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 04:22 PM Accepted by SEC EDGAR 08/17/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faller Douglas Vincent

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		A		3,516(1)	A	$1.65	33,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of base salary

	/s/ Susan Eylward, Attorney-in-Fact for Douglas Faller	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)